Brii Biosciences Limited filed its Monthly Return for Equity Issuer to the Hong Kong Stock Exchange on 7 July 2026, detailing share-capital movements for June 2026.

Authorised capital unchanged • Authorised share capital stood at 1.20 billion ordinary shares with a par value of USD 0.000005 each, totalling USD 6,000. No change was recorded during the month.

Issued share base edges higher • Issued shares (excluding treasury stock) increased by 46,559 to 721.85 million, a 0.01% rise versus May. • Treasury shares were unchanged at 12.72 million, keeping total issued shares at 734.58 million.

Breakdown of new issuance • 1,500 new shares were issued from the exercise of options under the 2023 Share Option Scheme, generating HKD 1,446 in proceeds. • 45,059 new shares were allotted under the Post-IPO Share Award Scheme. • A total of 12,691 restricted share units were cancelled during the month.

Outstanding equity incentives • Share options outstanding at 30 June 2026: – Pre-IPO Share Incentive Plan: 5.55 million options outstanding. – Post-IPO Share Option Scheme: 9.66 million options outstanding after 500 options lapsed. – 2023 Share Option Scheme: 24.54 million options outstanding after 1,500 exercised and 3,250 lapsed. Aggregate outstanding options under the three schemes equal 39.75 million shares.

• Share awards that may still be granted or vested include 1.25 million shares under the Post-IPO Share Award Scheme and 3.03 million shares under the 2023 Share Award Scheme.

Public float and other securities • The company affirmed compliance with the Main Board’s minimum 25% public-float requirement. • No movements were reported in warrants, convertible securities, or treasury-share balances during the month.

Capital structure snapshot (30 June 2026) • Authorised shares: 1.20 billion • Issued shares (ex-treasury): 721.85 million • Treasury shares: 12.72 million • Total issued shares: 734.58 million

The filing satisfies Hong Kong Listing Rule 13.25C disclosure requirements and confirms that all share issuances were duly authorised and executed in accordance with applicable regulations.